KODK · Eastman Kodak Company

Current Thesis

Eastman Kodak's materials pivot needs Q3 to repeat Q2's revenue and margin gains before the $9.20 market shelf fails. The 2026-08-04 results reported Advanced Materials & Chemicals (AM&C) revenue of $105 million, up 40% year over year, and consolidated gross margin of 26%. Those are the operating benchmarks for this thesis; a weekly close below $9.20 invalidates its price structure.

The change since the 2026-09-05 assessment is a recovery in measured momentum. The adjusted reference close was $9.55 on 2026-09-18, compared with $9.29 on 2026-09-04; the 14-day relative strength index (RSI) was 61.4, compared with 32.5. These observations establish a price recovery, but they do not identify its buyers or establish new demand for Kodak's battery and pharmaceutical products.

The narrative is maturing — the operating argument still rests on the 2026-08-04 results, while the 2026-09-18 close remains below the $10.00 reference close recorded on 2026-08-14. This is an inference about the story's development, not a measurement of investor participation. Kodak's event calendar lists the August results as its latest earnings event and provides no upcoming company event; no later operating catalyst was established by the research available on 2026-09-19. Kodak events and presentations

Bullish and bearish views on Eastman Kodak Company

The model's bull view on Eastman Kodak Company (KODK), in brief: Segment growth included higher earnings. The bear view: The product mix remains unresolved. The 2026-08-04 disclosures grouped film, pharmaceutical reagents and battery coating within AM&C without separate revenue figures for those businesses. The sample is too small to support a claim that battery or pharmaceutical commercialization… Both cases follow in full.

Bull Case

• Segment growth included higher earnings. Kodak's 2026-08-04 results reported Q2 AM&C revenue of $105 million versus $75 million a year earlier, with segment operational earnings before interest, taxes, depreciation and amortization (EBITDA) of $22 million versus $8 million. The improvement supports the materials argument, although the segment totals do not establish which product line drove it.
• Consolidated profitability also improved. The 2026-08-04 release reported Q2 gross profit of $82 million versus $51 million and gross margin of 26% versus 19%. Maintaining at least the Q2 margin alongside AM&C revenue of at least $105 million at the next quarterly report would satisfy the operating test defined here.
• Print revenue supported the quarter. Kodak's Q2 disclosure on 2026-08-04 reported Print revenue of $195 million, up 10% year over year. That reported growth means the quarter's improvement was broader than the materials segment alone.

Bear Case

• The product mix remains unresolved. The 2026-08-04 disclosures grouped film, pharmaceutical reagents and battery coating within AM&C without separate revenue figures for those businesses. The sample is too small to support a claim that battery or pharmaceutical commercialization caused the segment's growth.
• Silver costs challenge margin persistence. Management's 2026-08-04 earnings commentary described silver prices as more than double year-end levels and attributed the inventory build primarily to silver. A subsequent gross margin below Q2's 26%, accompanied by another silver-cost warning, would undermine the margin-persistence argument.
• Cash declined despite operating improvement. The Q2 filing reported cash of $290 million at 2026-06-30 versus $337 million at 2025-12-31, alongside $101 million of term-loan repayments, $87 million of pension redemption proceeds and a $37 million inventory increase. Those disclosed movements prevent the higher reported earnings from being treated as evidence of equivalent cash accumulation.

Setup & Price Structure

The 2026-09-18 adjusted close of $9.55 stands above the $9.20 shelf identified in the 2026-09-05 published assessment as reclaimed on the August results. It remains below the market's 2026-08-14 close of $10.00. These reference points describe a recovery within the earlier advance; the available closing observations do not establish an uninterrupted base or the absence of an intervening breach.

As of 2026-09-18, the shares were 34.2% below the reported 52-week high of $14.51 and had a three-month price change of -4.1%. RSI had recovered to 61.4. No moving-average value, current short-interest count or comparable participation series is available here, so neither extension above a rising average nor a crowded ownership structure can be established.

The 2026-07-01 resale registration cited in the earlier public coverage covered approximately 39.46 million shares and provided no proceeds to Kodak. Registration establishes potential secondary supply; it does not establish that those shares subsequently reached the market. The September momentum recovery alone provides no evidence of short covering or issuance into strength.

Catalyst Calendar (next 30 days)

Kodak's event calendar, reviewed on 2026-09-19, provides no confirmed company event for the coming window. The dated releases below concern positioning rather than operating performance. Kodak events and presentations

• 2026-09-24 — Short-interest publication. FINRA's calendar gives this publication date for the 2026-09-15 settlement snapshot. The release supplies a positioning observation associated with the September recovery; without the actual counts and a comparison period, no covering or crowding conclusion follows. FINRA reporting calendar
• 2026-10-09 — Short-interest publication. FINRA schedules publication of the 2026-09-30 settlement snapshot on this date. It supplies a subsequent observation, subject to the same reporting lag and interpretation limits. FINRA reporting calendar
• ~2026-11-10, estimated — Q3 results. This date appeared in the TipRanks calendar cited on 2026-09-05; Kodak's own calendar does not confirm it. Outside the next 30 days, the report is the operating test: AM&C revenue against Q2's $105 million, consolidated gross margin against 26%, and disclosure of battery or pharmaceutical commercial activity.

What Would Change Our Mind

Loss of the August results shelf would break the price-supported recovery thesis: a weekly close below $9.20 is the observable invalidation. That market level comes from the 2026-09-05 published assessment and remains the condition against which the 2026-09-18 recovery is judged.

The operating case plays out if Q3 reports AM&C revenue of at least $105 million and consolidated gross margin of at least 26% before that price invalidation occurs. Those thresholds are the actual Q2 figures reported on 2026-08-04, not management guidance. AM&C revenue below $105 million would fail the repeatability test; separate disclosure of battery or pharmaceutical revenue, or a named commercial agreement, would strengthen the attribution of growth to the proposed pivot.

Correlation Notes

This remains a single-company setup. The 2026-08-04 AM&C disclosure does not isolate battery or pharmaceutical revenue, so it cannot establish Kodak as a proxy for either industry. No matched return series is available to support a statistical correlation claim with those groups or with artificial-intelligence infrastructure equities.

Silver has a documented operating connection: management's 2026-08-04 commentary linked higher silver costs to inventory accumulation. That establishes an input-cost exposure, not a measured relationship between silver prices and Kodak's share price. The relevant company test is the subsequent gross-margin disclosure against Q2's 26% alongside management's explanation of input costs.